Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 15/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3565747 | 1.00 | AAK1 (0.65) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL28445012 | 0.88 | AAK1 (0.65) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL30175900 | 0.86 | AAK1 (0.49) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL1519234 | 0.86 | AAK1 (0.49) | AAK1NPC1RECQLRAB9ASMN1; SMN2 | |
| SCHEMBL22012941 | 0.85 | AAK1 (0.64) | AAK1SMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL29995455 | 0.85 | AAK1 (0.64) | AAK1SMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL64834 | 0.85 | AAK1 (0.53) | AAK1NPC1RAB9ASMN1; SMN2CYP17A1 | |
| SCHEMBL15160030 | 0.84 | GAA (0.52) | AAK1NPC1CYP17A1 | |
| SCHEMBL3410364 | 0.84 | HPGD (0.49) | AAK1SMN1; SMN2CYP17A1 | |
| SCHEMBL16515569 | 0.83 | AAK1 (0.69) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4714938-A1 | HDAC1/2 SELECTIVE INHIBITOR AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2026-03-25 | — | — | EP | disclosed |
| CN-119192135-A | HDAC1/2 selective inhibitors and uses thereof | 微境生物医药科技(上海)有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119176770-A | HDAC inhibitors, compositions and uses thereof | 艾立康药业股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| WO-2024235218-A1 | HDAC1/2 SELECTIVE INHIBITOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2024-11-21 | — | — | WO | disclosed |
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20230113588-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-13 | — | — | US | disclosed |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-11-03 | — | — | US | disclosed |
| US-11447453-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-09-20 | — | — | US | disclosed |
| US-11377423-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-3966196-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-03-16 | — | — | EP | disclosed |
| EP-3154954-B1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | CHP1, ERAP1, QSOX1 | AAK1 3831/4885NPC1 2957/4885RECQL 4131/4885 |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | ERAP1, CHP1, QSOX1 | AAK1 3666/4885NPC1 3102/4885RECQL 4409/4885 |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | ERAP1, CHP1, QSOX1 | AAK1 3774/4885NPC1 2881/4885RECQL 4322/4885 |
| US-11447453-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | AAK1 684/4885NPC1 2618/4885RECQL 4637/4885 |
| US-20230113588-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | AAK1 684/4885NPC1 2618/4885RECQL 4637/4885 |
| US-11377423-B2 | Inhibitors of histone deacetylase | HDAC3, HDAC1, HDAC11 | AAK1 1279/4885NPC1 59/4885RECQL 3564/4885 |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | AAK1 2227/4885NPC1 659/4885RECQL 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.